<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Lundstrom A</submitter><funding>STROKE-Riksförbundet</funding><funding>Foundation for Coagulation Research KI</funding><funding>Stockholms Läns Landsting</funding><pagination>708-719</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7340656</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(4)</volume><pubmed_abstract>Platelet microvesicles (PMV) have previously been found elevated in acute ischemic stroke (IS) and could be biomarkers for risk of recurrence. PMV surface antigens such as P-selectin and phosphatidylserine (PS) reflect platelet activation and procoagulance. Tissue factor-positive microvesicles (TF&lt;sup>+&lt;/sup>MV) are considered procoagulant, in particular if co-expressing PS. We enumerated MV subpopulations with these surface antigens in a cohort of 211 patients with primarily non-cardioembolic IS or transient ischemic attack (TIA) and investigated their association with long-term outcome. MV concentrations were determined by flow cytometry in the acute and convalescent phase. Primary outcome was a composite of fatal and non-fatal recurrent IS or myocardial infarction. Secondary outcomes were recurrent IS and all-cause mortality. Outcome events were obtained from Swedish registers during a follow-up of 1100 patient years. Concentrations of PS-positive and PS-negative MV populations were elevated in patients compared with healthy controls in both the acute and convalescent phase. PS&lt;sup>+&lt;/sup>TF&lt;sup>+&lt;/sup>PMV displayed pronounced elevations, median fold change 77 in the acute phase (p &lt; 0.0001) but were not associated with outcome, neither were PS&lt;sup>+&lt;/sup>P-selectin&lt;sup>+&lt;/sup>PMV. The only subpopulation positively associated with primary outcome was PS&lt;sup>-&lt;/sup>TF&lt;sup>+&lt;/sup>PMV, with adjusted hazard ratio of 1.86 (1.04-3.31, p = 0.036) by Cox regression. Unexpectedly, several MV subpopulations tended to be associated with reduced risk of poor long-term outcome. Our results suggest that PS&lt;sup>+&lt;/sup>TF&lt;sup>+&lt;/sup>PMV may be a promising marker for cerebral ischemia, and that the in vivo generation of PS&lt;sup>-&lt;/sup>MV after IS/TIA warrants further study. Future MV studies should ideally enumerate PS&lt;sup>+&lt;/sup> and PS&lt;sup>-&lt;/sup>MV subpopulations separately.</pubmed_abstract><journal>Translational stroke research</journal><pubmed_title>Prognostic Value of Circulating Microvesicle Subpopulations in Ischemic Stroke and TIA.</pubmed_title><pmcid>PMC7340656</pmcid><funding_grant_id>Regional agreement on Clinical Research</funding_grant_id><funding_grant_id>NA</funding_grant_id><pubmed_authors>Rooth E</pubmed_authors><pubmed_authors>Thalin C</pubmed_authors><pubmed_authors>Wallen H</pubmed_authors><pubmed_authors>Henriksson P</pubmed_authors><pubmed_authors>Gigante B</pubmed_authors><pubmed_authors>von Arbin M</pubmed_authors><pubmed_authors>Lundstrom A</pubmed_authors><pubmed_authors>Mobarrez F</pubmed_authors><pubmed_authors>Laska AC</pubmed_authors></additional><is_claimable>false</is_claimable><name>Prognostic Value of Circulating Microvesicle Subpopulations in Ischemic Stroke and TIA.</name><description>Platelet microvesicles (PMV) have previously been found elevated in acute ischemic stroke (IS) and could be biomarkers for risk of recurrence. PMV surface antigens such as P-selectin and phosphatidylserine (PS) reflect platelet activation and procoagulance. Tissue factor-positive microvesicles (TF&lt;sup>+&lt;/sup>MV) are considered procoagulant, in particular if co-expressing PS. We enumerated MV subpopulations with these surface antigens in a cohort of 211 patients with primarily non-cardioembolic IS or transient ischemic attack (TIA) and investigated their association with long-term outcome. MV concentrations were determined by flow cytometry in the acute and convalescent phase. Primary outcome was a composite of fatal and non-fatal recurrent IS or myocardial infarction. Secondary outcomes were recurrent IS and all-cause mortality. Outcome events were obtained from Swedish registers during a follow-up of 1100 patient years. Concentrations of PS-positive and PS-negative MV populations were elevated in patients compared with healthy controls in both the acute and convalescent phase. PS&lt;sup>+&lt;/sup>TF&lt;sup>+&lt;/sup>PMV displayed pronounced elevations, median fold change 77 in the acute phase (p &lt; 0.0001) but were not associated with outcome, neither were PS&lt;sup>+&lt;/sup>P-selectin&lt;sup>+&lt;/sup>PMV. The only subpopulation positively associated with primary outcome was PS&lt;sup>-&lt;/sup>TF&lt;sup>+&lt;/sup>PMV, with adjusted hazard ratio of 1.86 (1.04-3.31, p = 0.036) by Cox regression. Unexpectedly, several MV subpopulations tended to be associated with reduced risk of poor long-term outcome. Our results suggest that PS&lt;sup>+&lt;/sup>TF&lt;sup>+&lt;/sup>PMV may be a promising marker for cerebral ischemia, and that the in vivo generation of PS&lt;sup>-&lt;/sup>MV after IS/TIA warrants further study. Future MV studies should ideally enumerate PS&lt;sup>+&lt;/sup> and PS&lt;sup>-&lt;/sup>MV subpopulations separately.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Aug</publication><modification>2025-04-26T08:13:19.693Z</modification><creation>2025-04-06T12:35:26.691Z</creation></dates><accession>S-EPMC7340656</accession><cross_references><pubmed>31983048</pubmed><doi>10.1007/s12975-019-00777-w</doi></cross_references></HashMap>